Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Johnson and Johnson
Merck
Moodys
McKesson

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Lannett Co Inc Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for LANNETT CO INC, and when can generic versions of LANNETT CO INC drugs launch?

LANNETT CO INC has one hundred and thirty approved drugs.

There is one US patent protecting LANNETT CO INC drugs. There is one tentative approval on LANNETT CO INC drugs.

There are fifteen patent family members on LANNETT CO INC drugs in twelve countries and one hundred and fifteen supplementary protection certificates in twelve countries.

Summary for Lannett Co Inc
International Patents:15
US Patents:1
Tradenames:101
Ingredients:94
NDAs:130
Drug Master File Entries: 1

Drugs and US Patents for Lannett Co Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lannett Co Inc LOXAPINE SUCCINATE loxapine succinate CAPSULE;ORAL 090695-002 Sep 26, 2011 AB RX No No   Start Trial   Start Trial
Lannett Co Inc DIETHYLPROPION HYDROCHLORIDE diethylpropion hydrochloride TABLET, EXTENDED RELEASE;ORAL 091680-001 Oct 24, 2011 AB RX No Yes   Start Trial   Start Trial
Lannett Co Inc DRONABINOL dronabinol CAPSULE;ORAL 201463-003 May 18, 2018 AB RX No No   Start Trial   Start Trial
Lannett Co Inc THEOPHYLLINE theophylline SOLUTION;ORAL 091156-001 Apr 13, 2011 AA RX No Yes   Start Trial   Start Trial
Lannett Co Inc ZAROXOLYN metolazone TABLET;ORAL 017386-001 Approved Prior to Jan 1, 1982 AB RX Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for LANNETT CO INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Extended-release Capsules 40 mg ➤ Subscribe 2007-03-15
➤ Subscribe Extended-release Capsules 10 mg, 20 mg and 30 mg ➤ Subscribe 2005-05-13

Supplementary Protection Certificates for Lannett Co Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0513917 SPC/GB98/019 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION COMPRISING LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND ZIDOVUDINE; REGISTERED: UK EU/1/98/058/001 19980318; UK EU/1/98/058/002 19980318
0503785 91330 Luxembourg   Start Trial CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS)
1718641 SPC/GB12/028 United Kingdom   Start Trial PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
1389098 2013C/054 Belgium   Start Trial PRODUCT NAME: ADASUVE-LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225
0166287 96C0032 Belgium   Start Trial PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
McKinsey
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.